The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile
- 1 February 2004
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 40 (3), 342-351
- https://doi.org/10.1016/j.ejca.2003.08.015
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph NodesJournal of Clinical Oncology, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001
- ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapyEuropean Journal of Cancer, 2000
- Neoadjuvant chemotherapy in young breast cancer patients: correlation between response and relapse?European Journal of Cancer, 1999
- Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cmCancer, 1994
- Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?Cancer, 1994
- The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor statusVirchows Archiv, 1994
- c-erbB-2 expression in different histological types of invasive breast carcinoma.Journal of Clinical Pathology, 1991
- Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or MoreJNCI Journal of the National Cancer Institute, 1990